Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease
Open Access
- 23 September 2025
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (6) , e213954
Abstract
Identifying β-amyloid (Aβ) positivity is crucial for selecting candidates for Aβ-targeted therapies in early-stage Alzheimer disease (AD). While Aβ PET is accurate, its high cost limits routine use. Plasma p-tau217 testing offers a less invasive option but also incurs additional costs. Structural brain MRI, routinely used in cognitive assessments, can identify features predictive of Aβ positivity without extra expense. We evaluated a 2-stage workflow integrating MRI-based features and plasma p-tau217 to efficiently predict Aβ PET positivity in early-stage AD. This prospective cohort study included participants with mild cognitive impairment (MCI) or early Alzheimer-type dementia (ATD) from the Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD; Korea) and Alzheimer's Disease Neuroimaging Initiative (ADNI; US) cohorts. Eligible participants had a Clinical Dementia Rating score of 0.5, along with MRI, plasma p-tau217, and Aβ PET data. A random forest classifier predicting Aβ PET positivity was developed using MRI-based brain atrophy patterns and APOE ε4 status. Participants were stratified into low-risk, intermediate-risk, and high-risk groups; plasma p-tau217 testing was performed only in intermediate-risk individuals. Outcomes included positive predictive value (PPV), negative predictive value (NPV), and overall accuracy. A total of 807 K-ROAD participants (median age 72.0 years, 58.7% female) and 230 ADNI participants (median age 70.9 years, 49.1% female) were analyzed. Using a 95% sensitivity/specificity strategy, the low-risk group demonstrated NPVs of 94.7% (91.7%-97.7%, K-ROAD) and 99.0% (97.0%-100.0%, ADNI). The high-risk group showed PPVs of 97.6% (95.9%-99.3%, K-ROAD) and 98.8% (96.5%-100.0%, ADNI). Intermediate-risk groups comprised 33.3% (K-ROAD) and 20.9% (ADNI) of participants. Plasma p-tau217 testing in intermediate-risk groups yielded PPVs of 92.5% (88.7%-96.3%, K-ROAD) and 90.0% (79.0%-100.0%, ADNI) and NPVs of 83.1% (75.0%-91.2%, K-ROAD) and 83.3% (66.1%-100.0%, ADNI). The overall workflow accuracy was 94.2% (92.6%-95.8%, K-ROAD) and 96.5% (94.1%-98.9%, ADNI). The 2-stage diagnostic workflow integrating MRI-based risk stratification and plasma p-tau217 testing accurately identified individuals with Aβ PET positivity in early-stage AD, substantially reducing the need for additional biomarker testing. However, the generalizability may be limited by modest incremental improvement over baseline models and limited racial and ethnic diversity.Keywords
This publication has 50 references indexed in Scilit:
- Spatial patterns of brain amyloid- burden and atrophy rate associations in mild cognitive impairmentBrain, 2011
- Neuroimaging in DementiaNeurotherapeutics, 2011
- Neuroimaging of disorders leading to dementiaCurrent Neurology and Neuroscience Reports, 2008
- Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative databaseBrain, 2008
- The significance of medial temporal lobe atrophyNeurology, 2007
- Hippocampal atrophy in Alzheimer disease: Age mattersNeurology, 2006
- Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and MemoryThe Journal of Neuroscience, 2005
- Mild Cognitive ImpairmentArchives of Neurology, 1999
- Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal agingAmerican Journal of Roentgenology, 1987